Exciting news from our friends at Kineticos — the launch of Kinvard Bio, an anti-infectives biotech based on groundbreaking research that has been exclusively licensed from the Myers Lab at Harvard University and funded by the Kineticos AMR Accelerator Fund I (KAMRA I).









